摘要
AIM:To examine the effects of long-term proton pump inhibitor (PPI) therapy on body weight (BW) and body mass index (BMI) in patients with gastroesophageal reflux disease (GERD).METHODS: The subjects were 52 patients with GERD and 58 sex-and age-matched healthy controls. GERD patients were treated with PPI for a mean of 2.2 years (range, 0.8-5.7 years), and also advised on lifestyle modifications (e.g. selective diet, weight management). BW, BMI and other parameters were measured at baseline and end of study.RESULTS: Twenty-four GERD patients were treated daily with 10 mg omeprazole, 12 with 20 mg omeprazole, 8 with 10 mg rabeprazole, 5 with 15 mg lansoprazole, and 3 patients with 30 mg lansoprazole. At baseline, there were no differences in BW and BMI between reflux patients and controls. Patients with GERD showed increases in BW (baseline: 56.4±10.4 kg, end: 58.6±10.8 kg, mean±SD, P<0.0001) and BMI (baseline: 23.1±3.1 kg/m2, end: 24.0±3.1 kg/m2, P<0.001), but no such changes were noted in the control group. Mean BW increased by 3.5 kg (6.2% of baseline) in 37 (71%) reflux patients but decreased in only 6 (12%) patients during treatment.CONCLUSION: Long-term PPI treatment was associated with BW gain in patients with GERD. Reflux patients receiving PPI should be encouraged to manage BW through lifestyle modifi cations.
AIM： To examine the effects of long-term proton pump inhibitor （PPI） therapy on body weight （BW） and body mass index （BMI） in patients with gastroesophageal reflux disease （GERD）. METHODS： The subjects were 52 patients with GERD and 58 sex- and age-matched healthy controls. GERD patients were treated with PPI for a mean of 2.2 years （range, 0.8-5.7 years）, and also advised on lifestyle modifications （e.g. selective diet, weight management）. BW, BMI and other parameters were measured at baseline and end of study. RESULTS： Twenty-four GERD patients were treated daily with 10 mg omeprazole, 12 with 20 mg omeprazole, 8 with 10 mg rabeprazole, 5 with 15 mg lansoprazole, and 3 patients with 30 mg lansoprazole. At baseline, there were no differences in BW and BMI between reflux patients and controls. Patients with GERD showed increases in BW （baseline： 56.4 ± 10.4 kg, end： 58.6 ± 10.8 kg, mean ± SD, P 〈 0.0001） and BMI （baseline： 23.1 ± 3.1 kg/m^2, end： 24.0 ± 3.1 kg/m^2, P 〈 0.001）, but no such changes were noted in the control group. Mean BW increased by 3.5 kg （6.2% of baseline） in 37 （71%） reflux patients but decreased in only 6 （12%） patients during treatment. CONCLUSION： Long-term PPI treatment was associatedwith BW gain in patients with GERD. Reflux patients receiving PPI should be encouraged to manage BW through lifestyle modifications.
